Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.27%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.28, delivering a surprise of 34.88%.Over the last four quarters, the company has ...

Vivos Therapeutics (VVOS) Q1 2025 Earnings Call May 15, 2025 05:00 PM ET Speaker0 Good day, everyone, and welcome to the Vivo Therapeutics First Quarter twenty twenty five Earnings Call. At this time, participants are in a listen only mode. A question and answer session will follow management's remarks. This conference call is being recorded and replay for today's call will be available on the Investor Relations section of VIVO's website and will remain posted there for the next thirty days. I will now hand ...

Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated "Building on the pivotal changes we initiated in 2024, Vivos has continued to strategically position itself for growth in 2025. We've streamlined our operations and laid a rock-solid foundation for the future. The acquisition and integration of SCN will showcase our transformation, setting the stage for thousands of OSA patients to gain access to our devices from just this one acquisition. Coupled with the increasing adoption of our FDA-clea ...

Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Mark One) | Delaware | 81-3224056 | | --- | --- | | (State or other jurisdiction | (I.R.S. Employer | | of incorporation or organization) | Identification No.) | ☒ QUARTERLY REPORT PURSUA ...

Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6 to 17 [4] - The company's devices have received FDA clearance for treating all severity levels of OSA in adults and moderate to severe OSA in children [4] - Vivos' CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children [4] Industry Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed [5] - The disorder is linked to various serious chronic health conditions, indicating a significant unmet need in the market for effective treatment solutions [5] - Current solutions often fail to address the root causes of OSA, highlighting the importance of innovative approaches like those offered by Vivos [5] Upcoming Events - Vivos plans to release its first quarter 2025 financial results after market close on May 15, 2025, followed by a conference call at 5:00 p.m. ET to discuss the results and recent developments [1] - The conference call can be accessed via a dedicated phone line and will also be available as a live webcast on the company's website [2][3] Innovative Approach - The Vivos Method provides a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, aiming to improve patient outcomes in sleep health [7] - The company collaborates with healthcare providers, including dentists and sleep specialists, to address the complex needs of patients suffering from sleep-related disorders [6]

Wall Street expects a year-over-year increase in earnings on higher revenues when Vivos Therapeutics, Inc. (VVOS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating ...

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 34.88%. A quarter ago, it was expected that this company would post a loss of $0.70 per share when it actually produced a loss of $0.40, delivering a surprise of 42.86%. Over the last four quarters, the company h ...

Revenue Performance - Product revenue increased by 26% year over year, contributing to a total revenue of approximately $15.0 million for the full year ended December 31, 2024, compared to $13.8 million in 2023[2] - Total revenue increased to $15,031 million in 2024, up from $13,801 million in 2023, representing a growth of 8.9%[18] - Product revenue rose to $7,874 million in 2024, compared to $6,270 million in 2023, reflecting an increase of 25.6%[18] - Service revenue decreased to $7,157 million in 2024, down from $7,531 million in 2023, indicating a decline of 5%[18] Operating Performance - Operating expenses decreased by $5.4 million, or 21%, to $20.2 million for the full year ended December 31, 2024, reflecting ongoing cost-cutting initiatives[2] - Total operating expenses decreased to $20,190 million in 2024, down from $25,567 million in 2023, a reduction of 21%[18] - Operating loss reduced by $6.1 million, or 35%, to $11.2 million in 2024 from $17.3 million in 2023[2] - Operating loss narrowed to $(11,171) million in 2024, compared to $(17,296) million in 2023, showing an improvement of 35%[18] Profitability and Loss - Net loss for 2024 was $(11,136) million, an improvement from $(13,583) million in 2023, reflecting a reduction of 18%[18] - Net loss per share (basic and diluted) improved to $(2.22) in 2024 from $(11.14) in 2023[18] Cash and Liquidity - Cash and cash equivalents increased to $6.3 million as of December 31, 2024, following approximately $17.9 million raised through four equity transactions during the year[2] - The company raised $7.5 million from New Seneca Partners as part of its efforts to strengthen capital structure and improve liquidity[4] - Vivos aims to achieve cash flow positive operations and profitability in the foreseeable future, supported by its new strategic initiatives[4] Patient Treatment and Market Strategy - The number of patients treated with Vivos' patented oral appliances rose to approximately 58,000 worldwide, up from over 42,000 at the end of 2023[2] - Vivos received FDA clearance for the DNA appliance in September 2024, allowing treatment of moderate to severe OSA in children ages 6 to 17, complementing the 2023 clearance for adults[2] - The new marketing and distribution strategy focuses on contractual, profit-sharing alliances with sleep healthcare providers, initiated with Rebis Health Holdings in June 2024[3] - Vivos expects to present treatments to more patients and increase revenue per case, projecting contribution margins of approximately 50% per patient[5] Shareholder Information - Weighted average number of shares outstanding increased significantly to 5,019,886 in 2024 from 1,219,381 in 2023[18] - The company reported a change in fair value of warrant liability, net of issuance costs, which contributed positively in 2023 but was not present in 2024[18]